AZBio Expo 2011 Company Spotlight
The 2011 AZBio Expo brought together innovative and life saving companies from across the state along with leaders from across the industry.
Be sure to check out the highlights and a special spotlight interview where Don Isaacs, VP of Communications at SynCardia Systems, Inc. brings EmpowHER's Shana O'Conner up close and personal with the world's only Total Artificial Heart. It's why SynCardia was named the 2011 Bioscience Company of the Year.
Update from ASU Biodesign's Dr. Raymond DuBois
Dr. Ray DuBois, M.D., Ph.D. Dr. DuBois is a world-renowned physician-scientist who has devoted his career to understanding the linkages between inflammation and cancer, particularly colon cancer. He assumed his new role as Executive Director of the Biodesign Institute in December of 2012, coming by way of Houston as provost of the prestigious M.D. Anderson Cancer Center.
Industrial Biotech in Arizona
Where is Industrial Biotech in Arizona Today?Glen Galster, co-founder of Algae Biosciences and AZBio Chairman of the Board moderates this panel discussion from the AZBio Expo 2012 featuring:
Leif P. Christoffersen, Director of Biomass Integration, Yulex Corporation.
Ben Cloud, President and CEO, Phyco Biosciences, Inc.,
Josh Hottenstein, Cleantech Open
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes:
- First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart)
- First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard
- First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more
- First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA
- First imaging biomarker for trial enrichment qualified by the EMA
Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.